Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
复制标题
DOI：
10.1038/clpt.2013.254
复制
发表时间：
2014-04-01
影响因子：
6.7
通讯作者：
Skaar, T. C.
中科院分区：
文献类型：
--
作者：
Crews, K. R.;Gaedigk, A.;Skaar, T. C.
可待因被肝细胞色素 P450 2D6 (CYP2D6) 生物激活为吗啡（一种强阿片类激动剂）；因此，可待因的功效和安全性由 CYP2D6 活性决定。多态性是 CYP2D6 变异的主要原因。我们总结了支持这种关联的文献证据，并根据 CYP2D6 基因型提供可待因的治疗建议。本文件是 2012 年临床药物遗传学实施联盟 (CPIC) CYP2D6 基因型和可待因治疗指南的更新。
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.